STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2768 by analyst upside · 2026-06-27
WGS
GeneDx Holdings Corp.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+12.4%
implied upside to consensus target
Current Price $69.82
Consensus Target $78.44
Bull Target $100.0
Bear Target $55.0
Analysts Covering 9
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
8
Hold
0
Sell
0
52-Week Low $32.21
52-Week High $170.87
YTD Return -47.2%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E 56.7x
EPS (TTM) $-2.66
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $443M
Profit Margin -17.6%
52-WEEK RANGE
52-Week Low $32.21
52-Week High $170.87
Current Price $69.82
Bear Target $55.0
Bull Target $100.0
● Now $69.82 ● Target $78.44
TRADING DATA
Avg Volume 1.3M
YTD Return -47.2%
Analyst Count 9
Consensus Buy
Upside to Target +12.4%
Last Updated 2026-06-27

ANALYST SUMMARY

GeneDx Holdings Corp. (WGS) is currently trading at $69.82 with a Wall Street consensus price target of $78.44, implying potential upside of 12.4% over the next 12 months. 9 analysts currently cover WGS, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $100.0, while the most cautious has a target of $55.0.

WGS operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 47.2% year-to-date and is currently trading near the lower end of its 52-week range of $32.21 – $170.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for WGS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-05-05 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-05 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-05-05 62% win rate (8 calls)
BTIG — Reiterated
Buy → Buy 2026-05-05 38% win rate (8 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-04-20 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-03-30 62% win rate (8 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2026-02-24 14% win rate (7 calls)
BTIG — Reiterated
Buy → Buy 2026-02-24 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →